↓ Skip to main content

PLOS

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors

Overview of attention for article published in PLOS ONE, January 2014
Altmetric Badge

Mentioned by

twitter
3 X users
patent
2 patents

Readers on

mendeley
21 Mendeley
Title
Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors
Published in
PLOS ONE, January 2014
DOI 10.1371/journal.pone.0086843
Pubmed ID
Authors

Michael L. Megison, Lauren A. Gillory, Jerry E. Stewart, Hugh C. Nabers, Elizabeth Mroczek-Musulman, Alicia M. Waters, Jennifer M. Coleman, Virginia Kelly, James M. Markert, G. Yancey Gillespie, Gregory K. Friedman, Elizabeth A. Beierle

Abstract

Recently, investigators showed that mice with syngeneic murine gliomas that were treated with a neuroattenuated oncolytic herpes simplex virus-1 (oHSV), M002, had a significant increase in survival. M002 has deletions in both copies of the γ134.5 gene, enabling replication in tumor cells but precluding infection of normal cells. Previous studies have shown antitumor effects of other oHSV against a number of adult tumors including hepatocellular carcinoma and renal cell carcinoma. The purpose of the current study was to investigate the oncolytic potential of M002 against difficult to treat pediatric liver and kidney tumors. We showed that the oHSV, M002, infected, replicated, and decreased cell survival in hepatoblastoma, malignant rhabdoid kidney tumor, and renal sarcoma cell lines. In addition, we showed that in murine xenografts, treatment with M002 significantly increased survival and decreased tumor growth. Finally, these studies showed that the primary entry protein for oHSV, CD111 (nectin-1) was present in human hepatoblastoma and malignant rhabdoid kidney tumor specimens. We concluded that M002 effectively targeted these rare aggressive tumor types and that M002 may have potential for use in children with unresponsive or relapsed pediatric solid tumors.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 5%
Unknown 20 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 19%
Student > Doctoral Student 3 14%
Student > Master 3 14%
Student > Ph. D. Student 2 10%
Other 2 10%
Other 2 10%
Unknown 5 24%
Readers by discipline Count As %
Medicine and Dentistry 9 43%
Agricultural and Biological Sciences 2 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Unknown 8 38%